Orexigen Surges – Even if Regulators Aren’t Happy About It

Orexigen Surges – Even if Regulators Aren’t Happy About It

Orexigen Therapeutics Inc. (NASDAQ:OREX), Intrexon Corp. (NYSE:XON) and Voltari Corp. (NASDAQ:VLTC) ended the day well in the green this Tuesday. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Solazyme Inc. (NASDAQ:SZYM) and Allied Nevada Gold Corp. (NYSEMKT:ANV), on the other hand, hit market close in the red.

Sign up for our free newsletter

Odey’s Special Situations Fund highlights Formula One and Shaw

Crispin OdeyThe Odey Special Situations Fund was down 0.27% for April, compared to its benchmark, the MSCI World USD Index, which was up 4.65%. For the first four months of the year, the fund is up 8.4%, while its benchmark returned 9.8%. Q1 2021 hedge fund letters, conferences and more The Odey Special Situations Fund is Read More

Orexigen Rallies

Orexigen Therapeutics Inc. soared +31.95% after the drug maker said its diet pill has cardiovascular benefits. Regulators criticized the firm for releasing the data; however, investors seem not to be concerned. Farallon Capital has a stake in the biotech company.


Intrexon surged +19.72%, ending the day priced at $48.15. The stock, a Dan Loeb pick, has climbed nearly +75% year-to-date.

Carl Icahn investment Voltari Corp. rallied +14.4% to $0.94 this Tuesday and is up +43.88% for the year. It’s still trading far away from its 52-week high of $3.96.

Cyclacel Pharmaceuticals Plunges

Cyclacel Pharmaceuticals plunged -15.98%, ending the day at $1.42. Despite today’s dip, it’s up +147.47% over the past month. Billionaire Wilbur Ross has a small stake in the firm.

Solazyme Inc. tumbled -7.46% today. A maker of renewable oils and other bioproducts, the company recently won IP arbitration over a failed joint venture – news that broke yesterday. Chase Coleman’s Tiger Global has a 0.02% allocation in the company.

The share price of Allied Nevada Gold Corp. fell -7.29% to $0.86 – just cents away from its 52-week low of $0.72. John Paulson has a position in the firm.

Screen Shot 2015-02-23 at 3.00.26 PM


No posts to display